STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. + Spironolactone (drug)
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Histopathology Confirmed Supratentorial GBM at First Recurrence
Conditions
Histopathology Confirmed Supratentorial GBM at First Recurrence, IDHwt GBM, IDHm Grade 4 Astrocytoma
Trial Timeline
Apr 1, 2026 → May 1, 2027
NCT ID
NCT07431216About STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. + Spironolactone (drug)
STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle. + Spironolactone (drug) is a phase 1/2 stage product being developed by Lantern Pharma for Histopathology Confirmed Supratentorial GBM at First Recurrence. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07431216. Target conditions include Histopathology Confirmed Supratentorial GBM at First Recurrence, IDHwt GBM, IDHm Grade 4 Astrocytoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07431216 | Phase 1/2 | Recruiting |